http://jcps.bjmu.edu.cn

Journal of Chinese Pharmaceutical Sciences ›› 2022, Vol. 31 ›› Issue (3): 176-183.DOI: 10.5246/jcps.2022.03.015

• Original articles • Previous Articles     Next Articles

A pharmacological study of pioglitazone in the regulation of adipocyte differentiation

Chuan Qin, Qi Wan, Lei Xi, Mian Wei, Quan Du*()   

  1. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
  • Received:2021-10-11 Revised:2021-11-05 Accepted:2021-12-08 Online:2022-03-31 Published:2022-03-31
  • Contact: Quan Du

Abstract:

As a pathological result of the abnormal differentiation of adipocytes, the occurrence of obesity will not only lead to weight gain, abnormal energy metabolism, but also the development of the diseases such as diabetes. Early studies have focused on the discovery of protein factors that regulate this process. Recently, long noncoding RNAs (lncRNAs) are found to actively participate in the process of adipocyte differentiation. By means of literature investigation, we get to know that in the treatment of diabetes, taking pioglitazone for a long time will lead to weight gain and obesity. However, the undeerlying mechanisms are far from being clarified. To this aspect, the effects of pioglitazone treatment on adipocyte differentiation were systematically investigated, in the present study. Using an in vitro adipocyte differentiation model of 3T3-L1 cells, pioglitazone treatment was found to promot the process of differentiation. Studies were then performed with the effects on protein signaling pathway, in terms of the expressional regulation of PPARγ, C/EBPα, FABP4 and CD36. To further elucidate the effects of pioglitazone, regulation of a adipogenic lncRNA was also investigated in the study.

Key words: Long non-coding RNA, Adipocyte differentiation, Pioglitazone, slincRAD

Supporting: